Abstract
The aims of the study were to assess efficacy and safety of TNF-alpha antagonists (anti-TNF) in a cohort of patients with juvenile idiopathic arthritis (JIA) who began treatment under 4 years old and to assess relapse rate after methotrexate and/or anti-TNF withdrawal. We made a retrospective charts review of our non-systemic JIA patients treated with anti-TNF under 4 years of age between January 2006 and April 2013. Demographics, epidemiologic, clinical, laboratory data and rate of relapse after treatment withdrawal due to clinical remission were collected. Efficacy and safety end points included side effects (SE) and time to achieve clinical remission. We included 27 patients, 23 received etanercept and 4 adalimumab with a median age of 3.01 (range 0.88–3.97) years at anti-TNF beginning and 1.94 (range 0.18–5.44) and 2.39 (range 0.18–7.24) years of treatment and follow-up, respectively. All patients had previously received disease-modifying antirheumatic drugs at optimal dose. Nineteen patients reached clinical remission on treatment in a median time of 9.1 (range 6.23–21.17) months. Four of those relapsed during treatment. Six developed mild SE, mostly mild infections. No serious SE were described. Eleven patients who reached clinical remission relapsed after treatment withdrawal. None achieved clinical remission off treatment. Most patients reached clinical remission on anti-TNF. In our cohort of patients, etanercept and adalimumab were safe, with mostly mild infections and no serious SE. We observed a high relapse rate during treatment withdrawal.
References
Cassidy JT, Petty RE (2011) Chronic arthritis in childhood. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology, 6th edn. Elsevier Saunders, Philadelphia, pp 213–214
Modesto C, Antón J, Rodríguez B, Bou R, Arnal C, Ros J et al (2010) Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol 39:472–479
Huemer C, Huemer M, Dorner T, Falger J, Schacherl H, Bernecker M et al (2001) Incidence of pediatric rheumatic diseases in a regional population in Austria. J Rheumatol 28:2116–2119
Prieur AM, Le Gall E, Karman F, Edan C, Lasserre O, Goujard J (1987) Epidemiologic survey of juvenile chronic arthritis in France. Comparison of data obtained from two different regions. Clin Exp Rheumatol 5:217–223
Moe N, Rygg M (1998) Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin Exp Rheumatol 16:99–101
Kaipiainen-Seppanen O, Savolainen A (1996) Incidence of chronic juvenile rheumatic diseases in Finland during 1980–1990. Clin Exp Rheumatol 14:441–444
Shaw KL, Southwood TR, Duffy CM, McDonagh JE (2006) Health-related quality of life in adolescents with juvenile idiopathic arthritis. Arthritis Rheum 55:199–207
Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM et al (2007) Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization Multinational Quality of Life Cohort Study. Arthritis Rheum 57:35–43
Amine B, Rostom S, Benbouazza K, Abouqal R, Hajjaj-Hassouni N (2009) Health related quality of life survey about children and adolescents with juvenile idiopathic arthritis. Rheumatol Int 29:275–279
Feinstein AB, Forman EM, Masuda A, Cohen LL, Herbert JD, Moorthy LN et al (2001) Pain intensity, psychological inflexibility, and acceptance of pain as predictors of functioning in adolescents with juvenile idiopathic arthritis: a preliminary investigation. J Clin Psychol Med Settings 18:291–298
Katsicas MM, Russo RG (2009) Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 28:985–988
Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G (2008) Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int 28:1031–1034
Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A et al (2012) Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol 39:1287–1290
Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H (2014) Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiophatic arthritis aged 2 to 4 years. Clin Rheumatol. doi:10.1007/s1006701424981
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 31:390–392
Wallace C, Giannini E, Huang B, Itert L, Ruperto N (2011) American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 63:929–936
Iglesias E, Torrente-Segarra V, Bou R, Ricart S, González MI, Sánchez J et al (2014) Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment. Rheumatol Int 34:1053–1057
Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I et al (2011) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70:1704–1712
Pileggi GS, de Souza CB, Ferriani VP (2010) Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken) 62:1034–1039
Silva CA, Aikawa NE, Bonfa E (2013) Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol 9:532–543
Mellins ED, Macaubas C, Grom AA (2011) Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 7:416–426
Conflict of interest
No conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giménez-Roca, C., Iglesias, E., Torrente-Segarra, V. et al. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age. Rheumatol Int 35, 323–326 (2015). https://doi.org/10.1007/s00296-014-3103-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-014-3103-2